Literature DB >> 18676692

Mycobacterium bovis bacillus Calmette-Guerin therapy is a potent immunostimulator for management of systemic malignancies.

Shailendra Kapoor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18676692      PMCID： PMC2519312          DOI： 10.1128/CVI.00052-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


× No keyword cloud information.
  7 in total

1.  Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.

Authors:  Yasuyo Shintani; Yoshihisa Sawada; Takeshi Inagaki; Yasuo Kohjimoto; Yasunari Uekado; Toshiaki Shinka
Journal:  Int J Urol       Date:  2007-02       Impact factor: 3.369

2.  Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.

Authors:  Kesavan Esuvaranathan; Edmund Chiong; Thomas Paulraj Thamboo; Yiong Huak Chan; Revathi Kamaraj; Ratha Mahendran; Ming Teh
Journal:  Cancer       Date:  2007-03-15       Impact factor: 6.860

3.  Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.

Authors:  Fanghong Chen; Guanjian Zhang; Yanli Cao; Ryan Payne; William A See
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

4.  Mycobacterium bovis bacillus Calmette-Guerin induces CCL5 secretion via the Toll-like receptor 2-NF-kappaB and -Jun N-terminal kinase signaling pathways.

Authors:  Patricia Méndez-Samperio; Artemisa Trejo; Aline Pérez
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

5.  Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.

Authors:  Tomasz Demkow; Andrzej Alter; Paweł Wiechno
Journal:  Urol Int       Date:  2008-01-18       Impact factor: 2.089

6.  Intravesical Bacillus Calmette-Guerin for treatment of refractory interstitial cystitis.

Authors:  Seyed Mohammad Kazem Aghamir; Mohammd Ghasem Mohseni; Saeed Arasteh
Journal:  Urol J       Date:  2007       Impact factor: 1.510

7.  Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.

Authors:  Simon J Dovedi; John A Kirby; Barry R Davies; Hing Leung; John D Kelly
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.